Discovery of a Potent Parenterally Administered Factor XIa Inhibitor with Hydroxyquinolin-2(1H)-one as the P2' Moiety.

Structure-activity relationship optimization of phenylalanine P1' and P2' regions with a phenylimidazole core resulted in a series of potent FXIa inhibitors. Introducing 4-hydroxyquinolin-2-one as the P2' group enhanced FXIa affinity and metabolic stability. Incorporation of an N-methyl piperazine amide group to replace the phenylalanine improved both FXIa potency and aqueous solubility. Combination of the optimization led to the discovery of FXIa inhibitor 13 with a FXIa K i of 0.04 nM and an aPTT EC2x of 1.0 μM. Dose-dependent efficacy (EC50 of 0.53 μM) was achieved in the rabbit ECAT model with minimal bleeding time prolongation.

[1]  S. Sheriff,et al.  Structure-based design of inhibitors of coagulation factor XIa with novel P1 moieties. , 2015, Bioorganic & medicinal chemistry letters.

[2]  G. Raskob,et al.  Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis , 2014 .

[3]  A. Mathur,et al.  Phenylimidazoles as potent and selective inhibitors of coagulation factor XIa with in vivo antithrombotic activity. , 2014, Journal of medicinal chemistry.

[4]  P. Morin,et al.  Tetrahydroquinoline derivatives as potent and selective factor XIa inhibitors. , 2014, Journal of medicinal chemistry.

[5]  T. Renné,et al.  Plasma kallikrein: the bradykinin-producing enzyme , 2013, Thrombosis and Haemostasis.

[6]  J. Meijers,et al.  Anticoagulation beyond direct thrombin and factor Xa inhibitors: indications for targeting the intrinsic pathway? , 2013, Thrombosis and Haemostasis.

[7]  E. Feener,et al.  Role of plasma kallikrein in diabetes and metabolism , 2013, Thrombosis and Haemostasis.

[8]  Spinler Sarah.  The Pharmacology and Therapeutic Use of Dabigatran Etexilate , 2013, Journal of clinical pharmacology.

[9]  J. Weitz,et al.  Oral Direct Factor Xa Inhibitors , 2012, Circulation research.

[10]  B. Monia,et al.  Coagulation factor XI as a novel target for antithrombotic treatment , 2010, Journal of thrombosis and haemostasis : JTH.

[11]  D. Seiffert,et al.  Inhibition of Factor XIa as a New Approach to Anticoagulation , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[12]  A. Hillisch,et al.  Entering the era of non-basic p1 site groups: discovery of Xarelto (Rivaroxaban). , 2010, Current topics in medicinal chemistry.

[13]  Mark Crowther,et al.  Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.

[14]  James V Belcastro,et al.  An automated liquid chromatography-mass spectrometry process to determine metabolic stability half-life and intrinsic clearance of drug candidates by substrate depletion. , 2008, Assay and drug development technologies.

[15]  G. Lippi,et al.  Inherited factor XI deficiency: A concise review , 2006, Hematology.

[16]  G. Feuerstein,et al.  Effects of factor IX or factor XI deficiency on ferric chloride‐induced carotid artery occlusion in mice , 2005, Journal of thrombosis and haemostasis : JTH.

[17]  P. Lam,et al.  Nonpeptide Factor Xa Inhibitors III: Effects of DPC423, an Orally-Active Pyrazole Antithrombotic Agent, on Arterial Thrombosis in Rabbits , 2002, Journal of Pharmacology and Experimental Therapeutics.

[18]  E. Rosen,et al.  FXI Is Essential for Thrombus Formation Following FeCl3-Induced Injury of the Carotid Artery in the Mouse , 2002, Thrombosis and Haemostasis.

[19]  R. Hartmann,et al.  6-Substituted 1H-quinolin-2-ones and 2-methoxy-quinolines: synthesis and evaluation as inhibitors of steroid 5alpha reductases types 1 and 2. , 2000, European journal of medicinal chemistry.

[20]  R. Knabb,et al.  Nonpeptide factor Xa inhibitors II. Antithrombotic evaluation in a rabbit model of electrically induced carotid artery thrombosis. , 2000, The Journal of pharmacology and experimental therapeutics.

[21]  G. Broze,et al.  A murine model of factor XI deficiency. , 1997, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[22]  J. Hirsh,et al.  The international normalized ratio. A guide to understanding and correcting its problems. , 1994, Archives of internal medicine.

[23]  B. Morgan,et al.  Synthetic approaches to the ‘Azole’ peptide mimetics , 1993 .

[24]  R. Knabb,et al.  Chapter Nine - Case History: Eliquis™ (Apixaban), a Potent and Selective Inhibitor of Coagulation Factor Xa for the Prevention and Treatment of Thrombotic Diseases , 2012 .

[25]  C. Rowley.  Apixaban versus Warfarin in Patients with Atrial Fibrillation , 2012 .

[26]  D. Kubitza,et al.  The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor , 2011, Nature Reviews Drug Discovery.

[27]  T. Hua,et al.  Therapeutic level of oral anticoagulation with warfarin in patients with mechanical prosthetic heart valves: review of literature and recommendations based on international normalized ratio. , 1994, Postgraduate medical journal.